VectorY BV

VTx-002 is a first-in-class vectorized antibody to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review Amsterdam, The Netherlands, and Boston, MA — February 9, 2026 — VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its Phase 1/2 PIONEER-ALS trial evaluating VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in people with amyotrophic lateral sclerosis (ALS). The participant was treated at the lead clinical trial site, the Sean M. Healey & AMG Center for ALS at Mass General Brigham, a premier treatment center for neurodegenerative diseases and pioneering research. “ALS is a fatal neurodegenerative disease with no cure and only limited symptomatic treatment options available. The initiation of dosing in the PIONEER-ALS trial is a significant milestone for VectorY as we strive to transform the neurodegenerative disease landscape with novel disease-modifying approaches,” said Olga Uspenskaya-Cadoz M.D., Ph.D. and chief medical officer of VectorY. “This trial marks the first ever clinical evaluation of a therapy designed to holistically target TDP-43 pathology in ALS, and thereby reduce TDP-43 aggregation, correct mis-splicing abnormalities, and restore normal nuclear function, and we are excited to advance this novel potential therapeutic strategy to a community of patients who are actively looking for hope.” PIONEER-ALS is a multicenter, open label, dose-escalation Phase 1/2 clinical study that will evaluate two dose levels of VTx-002 and is expected to enroll 12 adults with ALS across sites in the U.S., Europe and the U.K. The primary objective of this study is to evaluate VTx-002 safety, tolerability, pharmacokinetics, and exploratory efficacy in people living with ALS. To optimize the path to pivotal clinical development, secondary and exploratory endpoints include assessment of the post-treatment Neurofilament light chain (NfL) and novel TDP-43 pathway-related biomarker trajectories, as well as clinical endpoints, including ALSFRS-R, slow-vital capacity, hand-held dynamometry and survival. “There remains a critical need for disease-modifying therapies in ALS. VTx-002 is engineered to enable sustained, localized delivery of an antibody targeting pathological TDP-43, a hallmark of ALS, with the goal of addressing a central driver of disease progression,” said Global Coordinating Investigator James Berry, MD, MPH, chief of the Division of Motor Neuron Diseases and director of the Neurological Clinical Research Institute (NCRI) at Mass General Brigham. “ The initiation of this study reflects an innovative approach aimed at one of the most important pathological features of the disease. I look forward to leading this exploration of VTx-002 and its potential to impact people living with ALS.” VectorY Therapeutics expects to continue enrolling participants in the PIONEER-ALS trial across multiple clinical sites. About VTx-002 VTx-002 is a first-in-class vectorized antibody therapeutic designed to target pathological TDP-43, a protein that aggregates abnormally in up to 97 percent of ALS patients. By leveraging a vector-based delivery platform, VTx-002 is designed to enable sustained antibody expression within the central nervous system, with the potential to address the underlying biology of ALS. More information about the PIONEER-ALS clinical trial can be found at: clinicatrials.gov : Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | ClinicalTrials.gov . About ALS ALS is a universally fatal neurodegenerative disease with no cure and only limited symptomatic treatment options. In the United States, more than 5,000 new cases of ALS are diagnosed each year, and more than 30,000 people are currently living with the disease. Median survival is 2–3 years after a diagnosis, and someone is either diagnosed with or dies from ALS every 90 minutes. The disease has an incidence comparable to major indications such as multiple sclerosis, yet far lower prevalence reflecting a persistent disease burden and urgent unmet medical need. About VectorY Therapeutics VectorY Therapeutics is dedicated to changing the trajectory of neurodegenerative diseases by developing precision-targeted, durable therapies that have the potential to arrest and ultimately reverse disease progression. With deep expertise in neurobiology, antibody engineering, and AAV-based delivery, VectorY is building a pipeline that includes VTx-002 targeting TDP-43 in ALS, VTx-001 targeting oxidized phospholipids in ALS, VTx-003 targeting mutant HTT and TDP-43 in Huntington’s disease, VTx-005 targeting phosphorylated tau in Alzheimer’s disease, and VTx-004 targeting TDP-43 in frontotemporal dementia (FTD). To learn more about the company, please visit our corporate website at Vectorytx.com and follow us on LinkedIn . Contacts VectorY Therapeutics B.V. E-mail: info@VectorYtx.com Tel: +31 20 226 8020 Instinctif Partners (Media) Julian Walker / Tim Pearson E-mail: VectorY@instinctif.com Tel: +44 207 802 2657

Experienced biotech executive brings more than 20 years of leadership experience in company creation, strategy, and drug development Amsterdam, The Netherlands, and Boston, MA — February 5, 2026 — VectoryY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today the appointment of Kevin Pojasek, Ph.D., to its Board of Directors. Dr. Pojasek brings more than two decades of expertise founding, scaling, and leading innovative biopharma companies, with deep expertise across corporate strategy, business development, and research and development. Dr. Pojasek is currently president and chief executive officer of Enara Bio, where he has led the company since 2018 and advanced its vision to develop T-cell engager therapies against novel solid tumor targets. He is also a Venture Partner at SV Health Investors and previously served as an Entrepreneur-in-Residence at Atlas Venture. Prior to Enara, Dr. Pojasek was chief strategy and business officer at Immunocore, where he played a key role to shape corporate and R&D strategy and led the company’s business development efforts. Earlier in his career, he co-founded Quartet Medicine while at Atlas Venture, serving as president and chief executive officer. He has held multiple executive leadership positions spanning research and development, corporate strategy and development at venture-backed biotechnology companies. “Kevin’s track record of building and guiding high-impact biotech companies makes him an exceptional addition to our board at VectorY,” said Adam Rosenberg, chair of the board at VectorY . “His strategic insight and deep industry experience will be invaluable as we continue to advance patient care with new and novel approaches to address unmet treatment needs in neurodegenerative disease.” “I’m pleased to join the VectorY team at this important stage of the company’s growth,” said Dr. Pojasek . “The company’s scientific mission to advance vectorized antibody therapies to create disease-modifying treatments that will potentially reverse neurodegenerative disease and transform patient care strongly resonates with me, and I look forward to supporting this talented team as they advance their platform and drive the next phase of growth and innovation.” Dr. Pojasek earned his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a Bachelor of Science degree in Molecular, Cellular, and Developmental Biology from the University of Colorado. About VectorY Therapeutics VectorY Therapeutics is dedicated to changing the trajectory of neurodegenerative diseases by developing precision-targeted, durable therapies that have the potential to arrest and ultimately reverse disease progression. With deep expertise in neurobiology, antibody engineering, and AAV-based delivery, VectorY is building a pipeline that includes VTx-002 targeting TDP-43 in ALS, VTx-001 targeting oxidized phospholipids in ALS, VTx-003 targeting mutant HTT and TDP-43 in Huntington’s disease, VTx-005 targeting phosphorylated tau in Alzheimer’s disease, and VTx-004 targeting TDP-43 in frontotemporal dementia (FTD). To learn more about the company, please visit our corporate website at Vectorytx.com and follow us on LinkedIn . Contacts VectorY Therapeutics B.V. E-mail: info@VectorYtx.com Tel: +31 20 226 8020 Instinctif Partners (Media) Julian Walker / Tim Pearson E-mail: VectorY@instinctifpartners.com Tel: +44 207 802 2657

~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~ ~ Milestone follows recent IND clearance and supports continued advancement of VTx-002 toward the planned PIONEER-ALS Phase 1/2 clinical study ~ AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). “ALS is a devastating and relentlessly progressive disease with profound unmet medical need, and patients urgently need new therapeutic options,” said Jim Scibetta, chief executive officer of VectorY. “The FDA’s decision to grant Fast Track designation to VTx-002 underscores the seriousness of ALS and the importance of advancing new investigational approaches. This designation enables closer and more frequent interaction with the FDA as we prepare to advance VTx-002 into the upcoming PIONEER-ALS Phase 1/2 clinical study, with the goal of moving as efficiently and responsibly as possible on behalf of patients.” Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose of Fast Track Designation is to get important new drugs to patients earlier. A therapy that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and may also be eligible for Priority Review in the future. VTx-002 targets TDP-43 pathology, which drives up to 97 percent of ALS cases. In December 2025, the Company announced that the FDA cleared its Investigational New Drug (IND) application for VTx-002 for the treatment of ALS and concurrently announced plans to initiate PIONEER-ALS, a Phase 1/2 clinical study designed to evaluate the safety, tolerability, and pharmacodynamic activity of VTx-002 in people living with ALS. VectorY intends to enroll its first patient in the PIONEER-ALS study in early 2026. About ALS ALS is a universally fatal neurodegenerative disease with no cure and only limited symptomatic treatment options. In the United States, more than 5,000 new cases of ALS are diagnosed each year, and more than 30,000 people are currently living with the disease. Median survival is 2–3 years after a diagnosis, and someone is either diagnosed with or dies from ALS every 90 minutes. The disease has an incidence comparable to major indications such as multiple sclerosis, yet far lower prevalence reflecting a persistent disease burden and urgent unmet medical need. About VectorY Therapeutics VectorY Therapeutics is dedicated to changing the trajectory of neurodegenerative diseases by developing precision-targeted, durable therapies that have the potential to arrest and ultimately reverse disease progression. With deep expertise in neurobiology, antibody engineering, and AAV-based delivery, VectorY is building a pipeline that includes VTx-002 targeting TDP-43 in ALS, VTx-001 targeting oxidized phospholipids in ALS, VTx-003 targeting mutant HTT and TDP-43 in Huntington’s disease, VTx-005 targeting phosphorylated tau in Alzheimer’s disease, and VTx-004 targeting TDP-43 in frontotemporal dementia (FTD). Contacts VectorY Therapeutics B.V. E-mail: info@VectorYtx.com Tel: +31 20 226 8020 Instinctif Partners (Media) Julian Walker / Tim Pearson E-mail: VectorY@instinctif.com Tel: +44 207 802 2657